Genprex (NASDAQ:GNPX) Trading Up 5.3%

Genprex, Inc. (NASDAQ:GNPX)’s stock price traded up 5.3% on Monday . The company traded as high as $2.72 and last traded at $2.57. 77,615 shares were traded during trading, an increase of 15% from the average session volume of 67,697 shares. The stock had previously closed at $2.44.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Genprex in a report on Wednesday, April 3rd.

Genprex Price Performance

The stock has a market cap of $5.40 million, a P/E ratio of -0.10 and a beta of -0.54. The business’s fifty day moving average price is $3.13 and its 200 day moving average price is $6.64.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Genprex stock. AMH Equity Ltd purchased a new position in shares of Genprex, Inc. (NASDAQ:GNPX) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 813,135 shares of the company’s stock, valued at approximately $321,000. Genprex accounts for 0.4% of AMH Equity Ltd’s investment portfolio, making the stock its 23rd largest holding. AMH Equity Ltd owned 1.37% of Genprex as of its most recent filing with the Securities and Exchange Commission (SEC). 14.05% of the stock is currently owned by institutional investors.

About Genprex

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes.